Sequential therapy involving an early switch from entecavir to pegylated interferon ‐α in Japanese patients with chronic hepatitis B

ConclusionThe outcomes of sequential therapy involving an early switch from entecavir to PegIFNα‐2a were unsatisfactory in Japanese patients with chronic hepatitis B. In addition to viral factors, host metabolic characteristics and liver fibrosis/tumor markers can be used for prediction of a sustained response to therapy, but accurate prediction of the therapeutic response is difficult.

Source: Hepatology Research - January 4, 2018 Category: Internal Medicine Authors: Masaru Enomoto, Shuhei Nishiguchi, Akihiro Tamori, Ritsuzo Kozuka, Hideki Fujii, Sawako Uchida ‐Kobayashi, Shinya Fukunishi, Yasuhiro Tsuda, Kazuhide Higuchi, Masaki Saito, Hirayuki Enomoto, Norifumi Kawada Tags: Original Article Source Type: research